Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
The current price of IVVD is $1.32 USD — it has decreased by -1.13% in the past 24 hours. Watch Invivyd stock price performance more closely on the chart.
What is Invivyd stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Invivyd stocks are traded under the ticker IVVD.
Is Invivyd stock price growing?▼
IVVD stock has fallen by -13.25% compared to the previous week, the month change is a -23.84% fall, over the last year Invivyd has showed a +126.21% increase.
What is Invivyd market cap?▼
Today Invivyd has the market capitalization of 306.56M
When is the next Invivyd earnings date?▼
Invivyd is going to release the next earnings report on May 07, 2026.
What were Invivyd earnings last quarter?▼
IVVD earnings for the last quarter are 0.02 USD per share, whereas the estimation was -0.08 USD resulting in a +124.01% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Invivyd revenue for the last year?▼
Invivyd revenue for the last year amounts to 50.77M USD.
What is Invivyd net income for the last year?▼
IVVD net income for the last year is -339.85M USD.
How many employees does Invivyd have?▼
As of April 02, 2026, the company has 99 employees.